|
[1]
|
Döhner, H., Wei, A.H., Appelbaum, F.R., Craddock, C., DiNardo, C.D., Dombret, H., Ebert, B.L., Fenaux, P., Godley, L.A., Hasserjian, R.P., et al. (2022) Diagnosis and Management of AML in Adults: 2022 Recommendations from an In-ternational Expert Panel on Behalf of the ELN. Blood, 140, 1345-1377. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Gross, S., Cairns, R.A., Minden, M.D., Driggers, E.M., Bittinger, M.A., Jang, H.G., Sasaki, M., Jin, S., Schenkein, D.P., Su, S.M., et al. (2010) Cancer-Associated Metabolite 2-Hydroxyglutarate Accumulates in Acute Myelogenous Leukemia with Isocitrate Dehydrogenase 1 and 2 Mutations. Journal of Experimental Medicine, 207, 339-344. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
DiNardo, C.D., Propert, K.J., Loren, A.W., Paietta, E., Sun, Z., Levine, R.L., Straley, K.S., Yen, K., Patel, J.P., Agresta, S., et al. (2013) Serum 2-Hydroxyglutarate Levels Predict Isocitrate Dehydrogenase Mutations and Clinical Outcome in Acute Myeloid Leukemia. Blood, 121, 4917-4924. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Dang, L., Yen, K. and Attar, E.C. (2016) IDH Mutations in Cancer and Progress toward Development of Targeted Therapeutics. Annals of Oncolog, 27, 599-608. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Jiang, L., Shestov, A.A., Swain, P., Yang, C., Parker, S.J., Wang, Q.A., Terada, L.S., Adams, N.D., McCabe, M.T., Pietrak. B., et al. (2016) Reductive Carboxylation Supports Redox Homeostasis during Anchorage-Independent Growth. Nature, 532, 255-258. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., et al. (2010) Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 18, 553-567. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Rakheja, D., Medeiros, L.J., Bevan, S. and Chen, W. (2013) The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neo-plasms. Frontiers in Oncology, 3, Article 169. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Kranendijk, M., Struys, E.A., van Schaftingen, E., Gibson, K.M., Kanhai, W.A., van der Knaap, M.S., Amiel, J., Buist, N.R., Das, A.M., de Klerk, J.B., et al. (2010) IDH2 Mutations in Patients with D-2-Hydroxyglutaric Aciduria. Science, 330, 336. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., et al. (2009) Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome. The New England Journal of Medicine, 361, 1058-1066. [Google Scholar] [CrossRef]
|
|
[10]
|
Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) IDH1 and IDH2 Mutations Are Frequent Ge-netic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1 Mutation without FLT3 Internal Tandem Duplication. Journal of Clinical Oncology, 28, 3636-3643. [Google Scholar] [CrossRef]
|
|
[11]
|
Losman, J. and Kaelin, W.G. (2013) What a Difference a Hydroxyl Makes: Mutant IDH, (R)-2-Hydroxyglutarate, and Cancer. Genes & Development, 27, 836-852. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Yang, H., Ye, D., Guan, K. and Xiong, Y. (2012) IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. Clinical Cancer Research, 18, 5562-5571. [Google Scholar] [CrossRef]
|
|
[13]
|
Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., et al. (2009) Cancer-Associated IDH1 Mutations Produce 2-Hydroxyglutarate. Nature, 462, 739-744. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., et al. (2010) The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell, 17, 225-234. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Koivunen, P., Lee, S., Duncan, C.G., Lopez, G., Lu, G., Ramkis-soon, S., Losman, J.A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) Transformation by the (R)-Enantiomer of 2-Hydroxyglutarate Linked to EGLN Activation. Nature, 483, 484-488. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Montalban-Bravo, G. and DiNardo, C.D. (2018) The Role of IDH Muta-tions in Acute Myeloid Leukemia. Future Oncology, 14, 979-993. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Lu, C., Ward, P.S., Kapoor, G.S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C.R., Khanin, R., Figueroa, M.E., Melnick, A., et al. (2012) IDH Mutation Impairs Histone Demethylation and Results in a Block to Cell Differentiation. Nature, 483, 474-478. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Clark, O., Yen, K. and Mellinghoff, I.K. (2016) Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clinical Cancer Research, 22, 1837-1842. [Google Scholar] [CrossRef]
|
|
[19]
|
Zhan, T., Rindtorff, N. and Boutros, M. (2017) Wnt Sig-naling in Cancer. Oncogene, 36, 1461-1473. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Chen, J., Lai, Y., Tsai, H., Kuo, C., Yen, B.L., Yeh, S., Sun, H.S. and Hung, W. (2016) The Oncometabolite R-2-Hy- droxyglutarate Activates NF-κB-Dependent Tumor-Promoting Stromal Niche for Acute Myeloid Leukemia Cells. Scientific Reports, 6, Article No. 32428. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Sasaki, M., Knobbe, C.B., Munger, J.C., Lind, E.F., Brenner, D., Brüstle, A., Harris, I.S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) IDH1 (R132H) Mutation Increases Murine Haema-topoietic Progenitors and Alters Epigenetics. Nature, 488, 656-659. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Chen, C., Liu, Y., Lu, C., Cross, J.R., Morris, J.P., Shroff, A.S., Ward, P.S., Bradner, J.E., Thompson, C. and Lowe, S.W. (2013) Cancer-Associated IDH2 Mutants Drive an Acute Myeloid Leukemia That Is Susceptible to Brd4 Inhibition. Genes & Development, 27, 1974-1985. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Kats, L.M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Straley, K., Karnik, R., Meissner, A., Small, D., et al. (2014) Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance. Cell Stem Cell, 14, 329-341. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Brunner, A.M., Neuberg, D.S., Wander, S.A., Sadrzadeh, H., Ballen, K.K., Amrein, P.C., Attar, E., Hobbs, G.S., Chen, Y.B., Perry, A., et al. (2019) Isocitrate Dehydrogenase 1 and 2 Mutations, 2-Hydroxyglutarate Levels, and Response to Standard Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia. American Cancer Society, 125, 541-549. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Abdel-Wahab, O., Patel, J. and Levine, R.L. (2011) Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML. Hematology/Oncology Clinics of North America, 25, 1119-1133. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Issa, G.C. and DiNardo, C.D. (2021) Acute Myeloid Leukemia with IDH1 and IDH2 Mutations: 2021 Treatment Algorithm. Blood Cancer Journal, 11, Article No. 107. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Chou, W., Lei, W., Ko, B., Hou, H., Chen, C., Tang, J., Yao, M., Tsay, W., Wu, S., Huang, S., et al. (2011) The Prognostic Impact and Stability of Isocitrate dehydrogenase 2 Mutation in Adult Patients with Acute Myeloid Leukemia. Leukemia, 25, 246-253. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Becker, J.S. and Fathi, A.T. (2020) Targeting IDH Mutations in AML: Wielding the Double-Edged Sword of Differentiation. Current Cancer Drug Targets, 20, 490-500. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Padmakumar, D., Chandraprabha, V.R., Gopinath, P., Vimala Devi, A.R.T., Anitha, G.R.J., Sreelatha, M.M., Padmakumar, A. and Sreedharan, H. (2021) A Concise Review on the Molecular Genetics of Acute Myeloid Leukemia. Leukemia Research, 111, Article ID: 106727. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation. Science, 340, 622-626. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Yen, K., Travins, J., Wang, F., David, M.D., Artin, E., Straley, K., Padyana, A., Gross, S., DeLaBarre, B., Tobin, E., et al. (2017) AG-221, a First-in-Class Therapy Targeting Acute Mye-loid Leukemia Harboring Oncogenic IDH2 Mutations. Cancer Discovery, 7, 478-493. [Google Scholar] [CrossRef]
|
|
[32]
|
Stein, E.M., DiNardo, C.D., Pollyea, D.A., Fathi, A.T., Ro-boz, G.J., Altman, J.K., Stone, R.M., DeAngelo, D.J., Levine, R.L., Flinn, I.W., et al. (2017) Enasidenib in Mutant IDH2 Relapsed or Refractory Acute Myeloid Leukemia. Blood, 130, 722-731. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Pollyea, D.A., Tallman, M.S., de Botton, S., Kantarjian, H.M., Collins, R., Stein, A.S., Frattini, M.G., Xu, Q., Tosolini, A., See, W.L., et al. (2019) Enasidenib, an Inhibitor of Mutant IDH2 Proteins, Induces Durable Remissions in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Leuke-mia, 33, 2575-2584. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
De Botton, S., Montesinos, P., Schuh, A.C., Papayannidis, C., Vyas, P., Wei, A.H., Ommen, H., Semochkin, S., Kim, H., Larson, R.A., et al. (2023) Enasidenib vs Conventional Care in Older Patients with Late-Stage Mutant-IDH2 Relapsed/Refractory AML: A Randomized Phase 3 Trial. Blood, 141, 156-167. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R., Collins, R.H., Mannis, G.N., Pollyea, D.A., et al. (2018) Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England Journal of Medicine, 378, 2386-2398. [Google Scholar] [CrossRef]
|
|
[36]
|
Roboz, G.J., DiNardo, C.D., Stein, E.M., de Botton, S., Mims, A.S., Prince, G.T., Altman, J.K., Arellano, M.L., Donnellan, W., Erba, H.P., et al. (2020) Ivosidenib Induces Deep Durable Remissions in Patients with Newly Diagnosed IDH1-Mutant Acute Myeloid Leukemia. Blood, 135, 463-471. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
De Botton, S., Fenaux, P., Yee, K.W.L., Récher, C., Wei, A.H., Montesinos, P., Taussig, D.C., Pigneux, A., Braun, T., Curti, A., et al. (2023) Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed or refractory IDH1-Mutated AML. Blood Advances. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
DiNardo, C.D., Hochhaus, A., Frattini, M.G., Yee, K., Zander, T., Krämer, A., Chen, X., Ji, Y., Parikh, N.S., Choi, J. and Wei, A.H. (2022) A Phase 1 Study of IDH305 in Pa-tients with IDH1R132-Mutant Acute Myeloid Leukemia or Myelodysplastic Syndrome. Journal of Cancer Research and Clinical Oncology, 149, 1145-1158. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Chaturvedi, A., Herbst, L., Pusch, S., Klett, L., Goparaju, R., Stichel, D., Kaulfuss, S., Panknin, O., Zimmermann, K., Toschi, L., et al. (2017) Pan-Mutant-IDH1 Inhibitor BAY1436032 Is Highly Effective against Human IDH1 Mutant Acute Myeloid Leukemia in Vivo. Leukemia, 31, 2020-2028. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Heuser, M., Palmisiano, N., Mantzaris, I., Mims, A., DiNardo, C., Silverman, L.R., Wang, E.S., Fiedler, W., Baldus, C., Schwind, S., et al. (2020) Safety and Efficacy of BAY1436032 in IDH1-Mutant AML: Phase I Study Results. Leukemia, 34, 2903-2913. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Chaturvedi, A., Gupta, C., Gabdoulline, R., Borchert, N.M., Go-paraju, R., Kaulfuss, S., Görlich, K., Schottmann, R., Othman, B., Welzenbach, J., et al. (2021) Synergistic Activity of IDH1 Inhibitor BAY1436032 with Azacitidine in IDH1 Mutant Acute Myeloid Leukemia. Haematologica, 106, 565-573. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Intlekofer, A.M., Shih, A.H., Wang, B., Nazir, A., Rustenburg, A.S., Albanese, S.K., Patel, M., Famulare, C., Correa, F.M., Takemoto, N., et al. (2018) Acquired Resistance to IDH In-hibition through Trans or Cis Dimer-Interface Mutations. Nature, 559, 125-129. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Choe, S., Wang, H., DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Watts, J.M., Pollyea. D.A., et al. (2020) Molecular Mechanisms Mediating Re-lapse following Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory AML. Blood Advances, 4, 1894-1905. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Quek, L., David, M.D., Kennedy, A., Metzner, M., Ama-tangelo, M., Shih, A., Stoilova, B., Quivoron, C., Heiblig, M., Willekens, C., et al. (2018) Clonal Heterogeneity of Acute Myeloid Leukemia Treated with the IDH2 Inhibitor Enasidenib. Nature Medicine, 24, 1167-1177. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Harding, J.J., Lowery, M.A., Shih, A.H., Schvartzman, J.M., Hou, S., Famulare, C., Patel, M., Roshal, M., Do, R.K., Zehir, A., et al. (2018) Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery, 8, 1540-1547. [Google Scholar] [CrossRef]
|
|
[46]
|
Wang, F., Morita, K., DiNardo, C.D., Furudate, K., Tanaka, T., Yan, Y., Patel, K.P., MacBeth, K.J., Wu, B., Liu, G., et al. (2021) Leukemia Stemness and Co-Occurring Mutations Drive Resistance to IDH Inhibitors in Acute Myeloid Leukemia. Nature Communications, 12, Article No. 260. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
MacBeth, K.J., Chopra, V.S., Tang, L., Zheng, B., Avanzino, B., See, W.L., Schwickart, M., Figueroa, M.E., Quek, L. and DiMartino, J.F. (2021) Combination of Azacitidine and Enasidenib Enhances Leukemic Cell Differentiation and Cooperatively Hypomethylates DNA. Experimental Hematology, 98, 47-52. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
DiNardo, C.D., Stein, A.S., Stein, E.M., Fathi, A.T., Frankfurt, O., Schuh, A.C., Döhner, H., Martinelli, G., Patel, P.A., Raffoux, E., et al. (2021) Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination with Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 39, 57-65. [Google Scholar] [CrossRef]
|
|
[49]
|
Montesinos, P., Recher, C., et al. (2022) Ivosidenib and Azacitidine inIDH1-Mutated AML. The New England Journal of Medicine, 386, 2535-2537. [Google Scholar] [CrossRef]
|
|
[50]
|
DiNardo, C.D., Schuh, A.C., Stein, E.M., Montesinos, P., Wei, A.H., de Botton, S., Zeidan, A.M., Fathi, A.T., Kantarjian, H.M., Bennett, J.M., et al. (2021) Enasidenib plus Azacitidine ver-sus Azacitidine Alone in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukaemia (AG221-AML-005): A Single-Arm, Phase 1b and Randomised, Phase 2 Trial. The Lancet Oncology, 22, 1597-1608. [Google Scholar] [CrossRef]
|
|
[51]
|
(2022) Ivosidenib Boosts OS with Azacitidine in AML. Cancer Discovery, 12, 1602-1603. [Google Scholar] [CrossRef]
|
|
[52]
|
Venugopal, S., Takahashi, K., Daver, N., Maiti, A., Borthakur, G., Loghavi, S., Short, N.J., Ohanian, M., Masarova, L., Issa, G., et al. (2022) Efficacy and Safety of Enasidenib and Azacitidine Combination in Patients with IDH2 Mutated Acute Myeloid Leukemia and Not Eligible for Intensive Chemotherapy. Blood Cancer Journal, 12, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Wei, A.H., Döhner, H., Pocock, C., Montesinos, P., Afanasyev, B., Dombret, H., Ravandi, F., Sayar, H., Jang, J., Porkka, K., et al. (2020) Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. The New England Journal of Medicine, 383, 2526-2537. [Google Scholar] [CrossRef]
|